Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma

Head and Neck

Volumn 35, Issue 12, 2013, Pages 1819-1828

  Albert, Sébastien ^a,b   Riveiro, Maria Eugenia ^c   Halimi, Caroline ^b   Hourseau, Muriel ^b   Couvelard, Anne ^b   Serova, Maria ^a,c   Barry, Béatrix ^b   Raymond, Eric ^a   Faivre, Sandrine ^a  

^a BEAUJON HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c AAREC Filia Research   (France)

Author keywords

epithelial to mesenchymal transition; head and neck cancer; hypoxia; invasion; metastasis; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MATRIX METALLOPROTEINASE; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL ACTIVATION; CELL FUNCTION; CELL INVASION; CELL MOTILITY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; HUMAN; METASTASIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EPITHELIAL-TO-MESENCHYMAL TRANSITION; HEAD AND NECK CANCER; HYPOXIA; INVASION; METASTASIS; SDF-1;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CHEMOKINE CXCL12; DRUG EVALUATION, PRECLINICAL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CXCR4;

EID: 84888002961     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23217     Document Type: Article

References (91)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Gourin CG, Podolsky RH,. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope 2006; 116: 1093-1106.
3. Westra WH,. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 2009; 3: 78-81.
4. Vokes EE, Cohen EE, Grandis JR,. Introduction: head and neck cancer. Semin Oncol 2008; 35: 196-197.
5. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP,. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987; 154: 439-442.
6. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
7. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353.
8. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW,. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
9. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JM, Garcia-Garcia A,. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett 2010; 295: 135-143.
10. Moulder JE, Rockwell S,. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5: 313-341.
11. Janot F, Cvitkovic E, Piekarski JD, et al. Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validation. Head Neck 1993; 15: 222-229.
12. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
13. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
14. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402.
15. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221-1232.
16. Sun X, Cheng G, Hao M, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709-722.
17. Vandercappellen J, Van Damme J, Struyf S,. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-244.
18. Wang JM, Deng X, Gong W, Su S,. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998; 220: 1-17.
19. Ransohoff RM,. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31: 711-721.
20. Feng Y, Broder CC, Kennedy PE, Berger EA,. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
21. Nagasawa T,. A chemokine PBSF/SDF-1 and its receptor CXCR4: function and involvement in HIV-1 infection. Seikagaku 1997; 69: 1373-1378.
22. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
23. Nagasawa T, Tachibana K, Kishimoto T,. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 1998; 10: 179-185.
24. Balkwill F,. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-179.
25. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM,. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167: 1676-1686.
26. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612.
27. Pan J, Mestas J, Burdick MD, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5:Art. 56.
28. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002; 86: 1250-1256.
29. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837.
30. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000; 6: 3530-3535.
31. Schimanski CC, Galle PR, Moehler M,. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol 2008; 14: 4721-4724.
32. Oliveira-Neto HH, Silva ET, Leles CR, et al. Involvement of CXCL12 and CXCR4 in lymph node metastases and development of oral squamous cell carcinomas. Tumour Biol 2008; 29: 262-271.
33. Almofti A, Uchida D, Begum NM, et al. The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol 2004; 25: 65-71.
34. Burger JA, Kipps TJ,. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767.
35. Teicher BA, Fricker SP,. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931.
36. Wong D, Korz W,. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008; 14: 7975-7980.
37. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330: 1066-1071.
38. Dessein AF, Stechly L, Jonckheere N, et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 2010; 70: 4644-4654.
39. Kruizinga RC, Bestebroer J, Berghuis P, et al. Role of chemokines and their receptors in cancer. Curr Pharm Des 2009; 15: 3396-3416.
40. Keeley EC, Mehrad B, Strieter RM,. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 2010; 106: 91-111.
41. Furusato B, Mohamed A, Uhlen M, Rhim JS,. CXCR4 and cancer. Pathol Int 2010; 60: 497-505.
42. Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534-2543.
43. Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005; 310: 117-130.
44. Chu CY, Cha ST, Chang CC, et al. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene 2007; 26: 2491-2501.
45. Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR,. Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 2010; 9:Art. 250.
46. Chabanon A, Desterke C, Rodenburger E, et al. A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin. Stem Cells 2008; 26: 3150-3161.
47. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154: 1125-1135.
48. Mirshahi F, Pourtau J, Li H, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000; 99: 587-594.
49. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-472.
50. Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007; 359: 716-722.
51. Woodhouse EC, Chuaqui RF, Liotta LA,. General mechanisms of metastasis. Cancer 1997; 80: 1529-1537.
52. Ou DL, Chien HF, Chen CL, Lin TC, Lin LI,. Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 2008; 28: 1355-1359.
53. Albert S, Hourseau M, Halimi C, et al. Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol 2012; 35: 312-321.
54. Ishikawa T, Nakashiro K, Hara S, et al. CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 2006; 28: 61-66.
55. Tan CT, Chu CY, Lu YC, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 2008; 29: 1519-1527.
56. Uchida D, Begum NM, Almofti A, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003; 290: 289-302.
57. Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y,. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 2937-2946.
58. Yin D, Gao Z,. Expression and clinical significance of chemokine receptor 4 in oral squamous cell carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi 2007; 25: 392-395.
59. Uchida D, Onoue T, Tomizuka Y, et al. Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 2007; 5: 685-694.
60. Zhang L, Yang C, Li M,. Expression of chemokine receptor CXCR4 and CCR7 in laryngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005; 19: 985-987, 991.
61. Delilbasi CB, Okura M, Iida S, Kogo M,. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 2004; 40: 154-157.
62. Ueda M, Shimada T, Goto Y, et al. Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx 2010; 37: 488-495.
63. Alvi A, Johnson JT,. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 1997; 19: 500-505.
64. Clatot F, Picquenot JM, Choussy O, et al. Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 1062-1068.
65. Samara GJ, Lawrence DM, Chiarelli CJ, et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 2004; 214: 231-241.
66. Rehman AO, Wang CY,. SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB. J Biol Chem 2008; 283: 19888-19894.
67. Hong JS, Pai HK, Hong KO, et al. CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells. J Oral Pathol Med 2009; 38: 214-219.
68. Yu T, Wu Y, Huang Y, et al. RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol Ther 2011; 20: 398-407.
69. Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007; 67: 7518-7524.
70. Rehman AO, Wang CY,. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int J Oral Sci 2009; 1: 105-118.
71. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008; 11: 123-151.
72. Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H, Sato M,. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 2006; 29: 1133-1138.
73. Taki M, Higashikawa K, Yoneda S, et al. Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 2008; 19: 993-998.
74. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN,. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 2003; 112: 169-180.
75. Bourboulia D, Stetler-Stevenson WG,. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20: 161-168.
76. Stetler-Stevenson WG,. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001; 10: 383-392.
77. Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L,. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 2011; 9: 161-172.
78. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
79. Uchida D, Begum NM, Tomizuka Y, et al. Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest 2004; 84: 1538-1546.
80. Pitkin L, Luangdilok S, Corbishley C, et al. Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. Br J Cancer 2007; 97: 670-677.
81. Shang ZJ, Liu K, Shao Z,. Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma. Oral Oncol 2009; 45: 480-485.
82. Wang J, Seethala RR, Zhang Q, et al. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst 2008; 100: 502-512.
83. Wang J, Xi L, Hunt JL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64: 1861-1866.
84. Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx 2006; 33: 37-42.
85. Christofakis EP, Miyazaki H, Rubink DS, Yeudall WA,. Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol 2008; 44: 920-926.
86. Gokhale AS, Haddad RI, Cavacini LA, et al. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol 2005; 41: 70-76.
87. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA,. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006; 66: 4279-4284.
88. Sato K, Ozawa S, Izukuri K, Kato Y, Hata R,. Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro. Cell Biol Int 2010; 34: 513-522.
89. Ito S, Ozawa S, Ikoma T, Yajima N, Kiyono T, Hata R,. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res 2010; 31: 199-206.
90. Izukuri K, Suzuki K, Yajima N, et al. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]. Transgenic Res 2010; 19: 1109-1117.
91. Wang J, Xi L, Gooding W, Godfrey TE, Ferris RL,. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 2005; 62: 121-133.